Pulse Biosciences, Inc. (PLSE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. on January 8, 2026. The filing reports the election of a new director and the appointment of that director to the Audit Committee, effective immediately.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
- Board Election: Maria Sainz was elected to the Board of Directors on January 8, 2026. Her term expires at the 2026 annual meeting of stockholders.
- Committee Appointment: Ms. Sainz was appointed to the Audit Committee.
- Compensation Structure:
- Cash Retainers: $55,000 annual retainer for Board service and $13,000 annual retainer for Audit Committee service, paid in quarterly installments.
- Initial Equity Grant: Option to purchase 50,000 shares. Vesting schedule: one-third on the one-year anniversary, with the remainder vesting monthly over the following two years.
- Future Equity Grants: Eligible for an annual option grant of 30,000 shares at each annual meeting, vesting monthly over one year.
- Retainer Option: Ms. Sainz may elect to convert cash retainers into options at a 3x multiplier of the cash value.
Outlook, Risks, and Management Commentary
The filing includes a press release (Exhibit 99.1) issued on January 9, 2026, announcing the appointment. Ms. Sainz brings over 30 years of healthtech operating experience, including roles as CEO at Hyperfine, Inc., AEGEA Medical, CardioKinetix Inc., and Concentric Medical. The filing states there are no family relationships between Ms. Sainz and other directors or officers, and no reportable related party transactions exist. No specific financial risks or contingencies were disclosed in this document.
Key Facts for Investor Verification
- Verify the impact of the new Audit Committee member on the company's financial oversight and internal controls.
- Review the total dilution impact of the initial 50,000 share option grant and potential future annual grants.
- Confirm the vesting conditions and exercise price of the options granted to Ms. Sainz in subsequent filings (e.g., Form 4).
- Assess how Ms. Sainz's background in commercial-stage medical devices and AI-powered MRI technology aligns with Pulse Biosciences' strategic direction.